Baumhefner said for many patients with breakthrough disease on standard IFNβ-1a, increasing the treatment dosage with twice-weekly therapy may be an acceptable alternative to switching treatments.
June Halper, MSN, MSCN, CMCS CEO, agreed, noting that "it makes a lot of sense for some patients to stay on a drug that has worked for them, and tweak the therapy if there is a breakthrough instead of automatically moving on to another drug," she told MedPage Today.
Baumhefner said a prospective, blinded, randomized trial comparing once-weekly and twice-weekly intramuscular IFNβ-1a may be warranted..
“There’s too much coincidence, though. They go over there perfectly healthy and come back sick, or in some cases are now dead,” Wisner said.